You are here:

diamorphine hydrochloride (Ayendi)

Advice

following an abbreviated submission:

diamorphine hydrochloride (Ayendi®) is accepted for use within NHS Scotland.

Indication under review: treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.

Unlicensed intranasal diamorphine has been used in the NHS in Scotland for the treatment of severe pain in children in the emergency setting. The availability of diamorphine hydrochloride nasal spray (Ayendi®) provides a licensed preparation.

Drug Details

Drug Name: diamorphine hydrochloride (Ayendi)
SMC Drug ID: 1172/16
Manufacturer: Wockhardt UK Ltd
Indication: Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 August 2016

Back